OnabotulinumtoxinA Add-On to Monoclonal Anti-CGRP Antibodies in Treatment-Refractory Chronic Migraine
Abstract
:1. Introduction
2. Results
2.1. Changes in Efficacy Headache Outcomes after Dual Therapy Compared to Baseline and Each Monotherapy Intervention
2.2. Changes in Disability, Quality of Life and Satisfaction Scales after Dual Therapy Compared to Baseline and Each Monotherapy Intervention
2.3. Safety Analysis
3. Discussion
4. Conclusions
5. Materials and Methods
Statistical Analysis
Author Contributions
Funding
Institutional Review Board Statement
Informed Consent Statement
Data Availability Statement
Conflicts of Interest
Competing Interests
References
- Headache Classification Committee of the International Headache Society (IHS). The International Classification of Headache Disorders, 3rd edition. Cephalalgia Int. J. Headache 2018, 38, 1–211. [Google Scholar] [CrossRef] [PubMed]
- Katsarava, Z.; Buse, D.C.; Manack, A.N.; Lipton, R.B. Defining the differences between episodic migraine and chronic migraine. Curr. Pain Headache Rep. 2012, 16, 86–92. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Andreou, A.P.; Edvinsson, L. Mechanisms of migraine as a chronic evolutive condition. J. Headache Pain. 2019, 20, 117. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Buse, D.C.; Greisman, J.D.; Baigi, K.; Lipton, R.B. Migraine Progression: A Systematic Review. Headache. 2019, 59, 306–338. [Google Scholar] [CrossRef]
- Dodick, D.W.; Turkel, C.C.; DeGryse, R.E.; Aurora, S.K.; Silberstein, S.D.; Lipton, R.B.; Diener, H.C.; Brin, M.F.; PREEMPT Chronic Migraine Study Group. OnabotulinumtoxinA for treatment of chronic migraine: Pooled results from the double-blind, randomized, placebo-controlled phases of the PREEMPT clinical program. Headache. 2010, 50, 921–936. [Google Scholar] [CrossRef]
- Argyriou, A.A.; Mitsikostas, D.D.; Mantovani, E.; Vikelis, M.; Tamburin, S. Beyond chronic migraine: A systematic review and expert opinion on the off-label use of botulinum neurotoxin type-A in other primary headache disorders. Expert Rev. Neurother. 2021, 21, 923–944. [Google Scholar] [CrossRef]
- Barbanti, P.; Egeo, G.; Fofi, L.; Aurilia, C.; Piroso, S. Rationale for use of onabotulinum toxin A (BOTOX) in chronic migraine. Neurol. Sci. 2015, 36 (Suppl. S1), 9–32. [Google Scholar] [CrossRef]
- García-Azorin, D.; Santos-Lasaosa, S.; Gago-Veiga, A.B.; Viguera Romero, J.; Guerrero-Peral, A.L. Real world preventative drug management of migraine among Spanish neurologists. J. Headache Pain 2019, 20, 19. [Google Scholar] [CrossRef] [Green Version]
- Diener, H.C.; Förderreuther, S.; Gaul, C.; Giese, F.; Hamann, T.; Holle-Lee, D.; Jürgens, T.P.; Kamm, K.; Kraya, T.; Lampl, C.; et al. Prevention of migraine with monoclonal antibodies against CGRP or the CGRP receptor: Addition to the S1 guideline: Therapy of migraine attacks and prevention of migraine. Recommendations of the Germany Society of Neurology and the German Migraine and Headache Society. Neurol. Res. Pract. 2020, 2, 11. [Google Scholar]
- Sacco, S.; Braschinsky, M.; Ducros, A.; Lampl, C.; Little, P.; van den Brink, A.M.; Pozo-Rosich, P.; Reuter, U.; de la Torre, E.R.; Sanchez Del Rio, M.; et al. European headache federation consensus on the definition of resistant and refractory migraine: Developed with the endorsement of the European Migraine & Headache Alliance (EMHA). J. Headache Pain 2020, 21, 76. [Google Scholar]
- Goadsby, P.J.; Holland, P.R.; Martins-Oliveira, M.; Hoffmann, J.; Schankin, C.; Akerman, S. Pathophysiology of Migraine: A Disorder of Sensory Processing. Physiol. Rev. 2017, 97, 553–622. [Google Scholar] [CrossRef] [PubMed]
- Ailani, J.; Burch, R.C.; Robbins, M.S.; Board of Directors of the American Headache Society. The American Headache Society Consensus Statement: Update on integrating new migraine treatments into clinical practice. Headache 2021, 61, 1021–1039. [Google Scholar] [CrossRef] [PubMed]
- Pellesi, L.; Do, T.P.; Ashina, H.; Ashina, M.; Burstein, R. Dual Therapy With Anti-CGRP Monoclonal Antibodies and Botulinum Toxin for Migraine Prevention: Is There a Rationale? Headache 2020, 60, 1056–1065. [Google Scholar] [CrossRef] [PubMed]
- Armanious, M.; Khalil, N.; Lu, Y.; Jimenez-Sanders, R. Erenumab and OnabotulinumtoxinA Combination Therapy for the Prevention of Intractable Chronic Migraine without Aura: A Retrospective Analysis. J. Pain Palliat. Care Pharmacother. 2020, 35, 1–6. [Google Scholar] [CrossRef] [PubMed]
- Ozudogru, S.N.; Bartell, J.W.; Yuan, H.; Digre, K.B.; Baggaley, S.K. The effect of adding calcitonin gene-related peptide monoclonal antibodies to onabotulinum toxin A therapy on headache burden: A retrospective observational case series. Headache 2020, 60, 1442–1443. [Google Scholar] [CrossRef]
- Boudreau, G.P. Treatment of chronic migraine with erenumab alone or as an add on therapy: A real-world observational study. Anesth. Pain Res. 2020, 4, 1–4. [Google Scholar] [CrossRef]
- Blumenfeld, A.M.; Frishberg, B.M.; Schim, J.D.; Iannone, A.; Schneider, G.; Yedigarova, L.; Adams, A.M. Real-World Evidence for Control of Chronic Migraine Patients Receiving CGRP Monoclonal Antibody Therapy Added to OnabotulinumtoxinA: A Retrospective Chart Review. Pain Ther. 2021, 10, 809–826. [Google Scholar] [CrossRef]
- Alpuente, A.; Gallardo, V.J.; Caronna, E.; Torres-Ferrús, M.; Pozo-Rosich, P. Partial and nonresponders to onabotulinumtoxinA can benefit from anti-CGRP monoclonal antibodies preventive treatment: A real-world evidence study. Eur. J. Neurol. 2021, 28, 2378–2382. [Google Scholar] [CrossRef]
- Mechtler, L.; Saikali, N.; McVige, J.; Hughes, O.; Traut, A.; Adams, A.M. Real-World Evidence for the Safety and Efficacy of CGRP Monoclonal Antibody Therapy Added to OnabotulinumtoxinA Treatment for Migraine Prevention in Adult Patients With Chronic Migraine. Front. Neurol. 2022, 12, 788159. [Google Scholar] [CrossRef] [PubMed]
- Nandyala, A.S.; Suri, H.; Dougherty, C.O.; Ailani, J. A retrospective evaluation of the combination of erenumab and onabotulinumtoxinA for the prevention of chronic migraine. Clin. Neurol. Neurosurg. 2022, 215, 107200. [Google Scholar] [CrossRef]
- Silvestro, M.; Tessitore, A.; Scotto di Clemente, F.; Battista, G.; Tedeschi, G.; Russo, A. Additive Interaction Between Onabotulinumtoxin-A and Erenumab in Patients With Refractory Migraine. Front. Neurol. 2021, 12, 656294. [Google Scholar] [CrossRef] [PubMed]
- Toni, T.; Tamanaha, R.; Newman, B.; Liang, Y.; Lee, J.; Carrazana, E.; Vajjala, V.; Viereck, J.; Liow, K.K. Effectiveness of dual migraine therapy with CGRP inhibitors and onabotulinumtoxinA injections: Case series. Neurol. Sci. Off. J. Ital. Neurol. Soc. Ital. Soc. Clin. Neurophysiol. 2021, 42, 5373–5376. [Google Scholar] [CrossRef] [PubMed]
- Suri, H.; Nandyala, A.; Dougherty, C.; Ailani, J. Combination of erenumab and onabotulinum toxin A is a safe and effective treatment for chronic migraine [poster]. 62nd Annu. Meet. Am. Headache Soc. Headache 2020, 60 (Suppl. S1), 9–10. [Google Scholar]
- Scuteri, D.; Tonin, P.; Nicotera, P.; Vulnera, M.; Altieri, G.C.; Tarsitano, A.; Bagetta, G.; Corasaniti, M.T. Pooled Analysis of Real-World Evidence Supports Anti-CGRP mAbs and OnabotulinumtoxinA Combined Trial in Chronic Migraine. Toxins 2022, 14, 529. [Google Scholar] [CrossRef]
- Zhang, X.; Strassman, A.M.; Novack, V.; Brin, M.F.; Burstein, R. Extracranial injections of botulinum neurotoxin type A inhibit intracranial meningeal nociceptors’ responses to stimulation of TRPV1 and TRPA1 channels: Are we getting closer to solving this puzzle? Cephalalgia Int. J. Headache 2016, 36, 875–886. [Google Scholar] [CrossRef]
- Melo-Carrillo, A.; Strassman, A.M.; Nir, R.R.; Schain, A.J.; Noseda, R.; Stratton, J.; Burstein, R. Fremanezumab-A Humanized Monoclonal Anti-CGRP Antibody-Inhibits Thinly Myelinated (Aδ) But Not Unmyelinated (C) Meningeal Nociceptors. J. Neurosci. Off. J. Soc. Neurosci. 2017, 37, 10587–10596. [Google Scholar] [CrossRef] [Green Version]
- Melo-Carrillo, A.; Strassman, A.M.; Schain, A.J.; Noseda, R.; Ashina, S.; Adams, A.; Brin, M.F.; Burstein, R. Exploring the effects of extracranial injections of botulinum toxin type A on prolonged intracranial meningeal nociceptors responses to cortical spreading depression in female rats. Cephalalgia Int. J. Headache 2019, 39, 1358–1365. [Google Scholar] [CrossRef]
- Edvinsson, J.; Warfvinge, K.; Krause, D.N.; Blixt, F.W.; Sheykhzade, M.; Edvinsson, L.; Haanes, K.A. C-fibers may modulate adjacent Aδ-fibers through axon-axon CGRP signaling at nodes of Ranvier in the trigeminal system. J. Headache Pain 2019, 20, 105. [Google Scholar] [CrossRef] [Green Version]
- Nowaczewska, M.; Straburzyński, M.; Waliszewska-Prosół, M.; Meder, G.; Janiak-Kiszka, J.; Kaźmierczak, W. Cerebral Blood Flow and Other Predictors of Responsiveness to Erenumab and Fremanezumab in Migraine—A Real-Life Study. Front. Neurol. 2022, 13, 895476. [Google Scholar] [CrossRef]
- Vikelis, M.; Argyriou, A.A.; Dermitzakis, E.V.; Spingos, K.C.; Mitsikostas, D.D. Onabotulinumtoxin-A treatment in Greek patients with chronic migraine. J. Headache Pain 2016, 17, 84. [Google Scholar] [CrossRef] [Green Version]
- Vikelis, M.; Argyriou, A.A.; Dermitzakis, E.V.; Spingos, K.C.; Makris, N.; Kararizou, E. Sustained onabotulinumtoxinA therapeutic benefits in patients with chronic migraine over 3 years of treatment. J. Headache Pain 2018, 19, 87. [Google Scholar] [CrossRef] [PubMed]
- Dermitzakis, E.V.; Vikelis, M.; Vlachos, G.S.; Argyriou, A.A. Assessing the Significance of the Circadian Time of Administration on the Effectiveness and Tolerability of OnabotulinumtoxinA for Chronic Migraine Prophylaxis. Toxins 2022, 14, 296. [Google Scholar] [CrossRef] [PubMed]
- Argyriou, A.A.; Dermitzakis, E.V.; Vlachos, G.S.; Vikelis, M. Long-term adherence, safety, and efficacy of repeated onabotulinumtoxinA over five years in chronic migraine prophylaxis. Acta Neurol. Scand. 2022, 145, 676–683. [Google Scholar] [CrossRef] [PubMed]
- Stewart, W.F.; Lipton, R.B.; Kolodner, K.; Liberman, J.; Sawyer, J. Reliability of the migraine disability assessment score in a population-based sample of headache sufferers. Cephalalgia Int. J. Headache 1999, 19, 107–174. [Google Scholar] [CrossRef] [PubMed]
- Kosinski, M.; Bayliss, M.S.; Bjorner, J.B.; Ware, J.E.; Garber, W.H., Jr.; Batenhorst, A.; Cady, R.; Dahlöf, C.G.; Dowson, A.; Tepper, S. A six-item short-form survey for measuring headache impact: The HIT-6. Qual. Life Res. Int. J. Qual. Life Asp. Treat. Care Rehabil. 2003, 12, 963–974. [Google Scholar] [CrossRef]
- Rabin, R.; de Charro, F. EQ-5D: A measure of health status from the EuroQol Group. Ann. Med. 2001, 33, 337–343. [Google Scholar] [CrossRef]
- Hurst, H.; Bolton, J. Assessing the clinical significance of change scores recorded on subjective outcome measures. J. Manip. Physiol. Ther. 2004, 27, 26–35. [Google Scholar] [CrossRef]
- Dworkin, R.H.; Turk, D.C.; Wyrwich, K.W.; Beaton, D.; Cleeland, C.S.; Farrar, J.T.; Haythornthwaite, J.A.; Jensen, M.P.; Kerns, R.D.; Ader, D.N.; et al. Interpreting the clinical importance of treatment outcomes in chronic pain clinical trials: IMMPACT recommendations. J. Pain 2008, 9, 105–121. [Google Scholar] [CrossRef]
Participants n = 19 | N (%) |
Variable | |
Gender | |
Females | 16 (84.2) |
Males | 3 (15.8) |
Age ± SD (range) | 42.1 ± 10.1 (24–65) |
Previous lines of prophylactic medications Median value (range) | 5 (3–7) |
Years ± SD (range) with chronic migraine | 10.1 ± 3.9 (6–18) |
Psychiatric comorbidities | 17 (89.5) |
Anxiety disorder | 3 |
Depression | 4 |
Mixed anxiety and depression disorder | 9 |
Bipolar disorder | 1 |
Medication overuse headache | |
Yes | 17 (89.5) |
No | 2 (10.5) |
Previous courses of BTX median (range) | 4 (3–5) |
Previous courses of anti-CGRP MAb median (range) | 5 (3–7) |
Specific anti-CGRP Mab | |
Erenumab 140 mg every 28 days | 2 (10.5) |
Fremanezumab 225 mg every 30 days | 17 (89.5) |
Publisher’s Note: MDPI stays neutral with regard to jurisdictional claims in published maps and institutional affiliations. |
© 2022 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
Share and Cite
Argyriou, A.A.; Dermitzakis, E.V.; Xiromerisiou, G.; Vikelis, M. OnabotulinumtoxinA Add-On to Monoclonal Anti-CGRP Antibodies in Treatment-Refractory Chronic Migraine. Toxins 2022, 14, 847. https://doi.org/10.3390/toxins14120847
Argyriou AA, Dermitzakis EV, Xiromerisiou G, Vikelis M. OnabotulinumtoxinA Add-On to Monoclonal Anti-CGRP Antibodies in Treatment-Refractory Chronic Migraine. Toxins. 2022; 14(12):847. https://doi.org/10.3390/toxins14120847
Chicago/Turabian StyleArgyriou, Andreas A., Emmanouil V. Dermitzakis, Georgia Xiromerisiou, and Michail Vikelis. 2022. "OnabotulinumtoxinA Add-On to Monoclonal Anti-CGRP Antibodies in Treatment-Refractory Chronic Migraine" Toxins 14, no. 12: 847. https://doi.org/10.3390/toxins14120847
APA StyleArgyriou, A. A., Dermitzakis, E. V., Xiromerisiou, G., & Vikelis, M. (2022). OnabotulinumtoxinA Add-On to Monoclonal Anti-CGRP Antibodies in Treatment-Refractory Chronic Migraine. Toxins, 14(12), 847. https://doi.org/10.3390/toxins14120847